Company intelligence / Profile preview

Biovelocita

Paris, France

Ownership: Private
Development stage: Other

Overview

Biovelocita, under the Sofinnova Partners platform, has launched and supported multiple early-stage biotech startups focused on high-impact diseases such as Alzheimer's disease and fibrosis. The firm provides direct management, financial support, and company-building expertise; most portfolio companies are at the pre-clinical or early translational stage with several newcos launched across Europe.[1][2][3][5]

Modalities: Cell therapySmall moleculeBiologic
Industry: Investors

Partnerships

AmgenBristol Myers SquibbPfizer VenturesUniversity of EdinburghGustave Roussy Institute

Beyond the preview

Go deeper on Biovelocita.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Biovelocita.

Explore the full profile